Foghorn Therapeutics Statistics Share Statistics Foghorn Therapeutics has 56.53M
shares outstanding. The number of shares has increased by 0.75%
in one year.
Shares Outstanding 56.53M Shares Change (YoY) 0.75% Shares Change (QoQ) 0.23% Owned by Institutions (%) 61.8% Shares Floating 26.76M Failed to Deliver (FTD) Shares 2,499 FTD / Avg. Volume 2.1%
Short Selling Information The latest short interest is 895.99K, so 1.61% of the outstanding
shares have been sold short.
Short Interest 895.99K Short % of Shares Out 1.61% Short % of Float 2.44% Short Ratio (days to cover) 10.14
Valuation Ratios The PE ratio is -2.99 and the forward
PE ratio is -4.19.
Foghorn Therapeutics's PEG ratio is
0.09.
PE Ratio -2.99 Forward PE -4.19 PS Ratio 11.46 Forward PS 7.6 PB Ratio -5.69 P/FCF Ratio -2.56 PEG Ratio 0.09
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Foghorn Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.73,
with a Debt / Equity ratio of -0.82.
Current Ratio 3.73 Quick Ratio 3.73 Debt / Equity -0.82 Debt / EBITDA -0.38 Debt / FCF -0.37 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $201.8K Profits Per Employee $-773.39K Employee Count 112 Asset Turnover 0.08 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -48.08% in the
last 52 weeks. The beta is 3.05, so Foghorn Therapeutics's
price volatility has been higher than the market average.
Beta 3.05 52-Week Price Change -48.08% 50-Day Moving Average 5.3 200-Day Moving Average 4.74 Relative Strength Index (RSI) 44.58 Average Volume (20 Days) 119,214
Income Statement In the last 12 months, Foghorn Therapeutics had revenue of 22.6M
and earned -86.62M
in profits. Earnings per share was -1.58.
Revenue 22.6M Gross Profit 22.6M Operating Income -102.68M Net Income -86.62M EBITDA -97.17M EBIT -100.28M Earnings Per Share (EPS) -1.58
Full Income Statement Balance Sheet The company has 55.45M in cash and 37.13M in
debt, giving a net cash position of 18.32M.
Cash & Cash Equivalents 55.45M Total Debt 37.13M Net Cash 18.32M Retained Earnings -558.18M Total Assets 226.24M Working Capital 126.06M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -100.41M
and capital expenditures -906K, giving a free cash flow of -101.31M.
Operating Cash Flow -100.41M Capital Expenditures -906K Free Cash Flow -101.31M FCF Per Share -1.85
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -454.31% and -383.24%.
Gross Margin 100% Operating Margin -454.31% Pretax Margin -383.24% Profit Margin -383.24% EBITDA Margin -429.9% EBIT Margin -454.31% FCF Margin -448.24%
